Insulet Reports Third Quarter 2026 Results
Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency1)
Category
344 releases
Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency1)
Achieved $60.1 million in RYTELO® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027
-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking…
Organic revenue increased 1.6% year-on-year on stable volume and positive price/mix Strong cash flow with lower exceptional item adjustments 2026…
- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -
Return on Average Equity climbs to 15.5% in Q3
Double-Digit Growth in Recorded Music Driven by Digital and Neighboring Rights Outlook for Revenue and Adjusted EBITDA Raised for Fiscal 2027 NEW…
Wayfair Inc. ("Wayfair," "we," or "our") (NYSE: W), the destination for all things home, today reported financial results for its third quarter ended…
Marketplace commercial vehicles sold growth of 46% YoY Marketplace dealer vehicles sold growth of 10% YoY, driven by 22% growth in US dealer vehicles…
•Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with…